Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in Transitional Liver Cell Tumors（TLCT）and Refractory Hepatoblastoma for Young Adolescent and Pediatric Participants After Chemotherapy：a Cohort Study

NCT05322187 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05322187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in Transitional Liver Cell Tumors（TLCT）and Refractory Hepatoblastoma for Young Adolescent and Pediatric Participants After Chemotherapy：a Cohort Study
Lead sponsor
RenJi Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 10, 2022
Completion date
December 31, 2023
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatoblastoma, liver cancer, pediatric cancer, pediatric solid tumor, transitional cell tumor